{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T09:44:22Z","timestamp":1790675062290,"version":"4.1.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T00:00:00Z","timestamp":1737072000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T00:00:00Z","timestamp":1737072000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"AstraZeneca"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s00280-024-04743-8","type":"journal-article","created":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T00:45:40Z","timestamp":1737074740000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Population pharmacokinetics and exposure-response analysis of durvalumab in combination with gemcitabine and cisplatin in patients with advanced biliary tract cancer"],"prefix":"10.1007","volume":"95","author":[{"given":"Aburough","family":"Abegesah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Do-Youn","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"KyoungSoo","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunling","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecil","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Xynos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Zotkiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Phipps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Gibbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diansong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,17]]},"reference":[{"key":"4743_CR1","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/S0140-6736(21)00153-7","volume":"397","author":"JW Valle","year":"2021","unstructured":"Valle JW, Kelley RK, Nervi B, Oh DY, Zhu AX (2021) Biliary tract cancer. Lancet 397:428\u2013444. https:\/\/doi.org\/10.1016\/S0140-6736(21)00153-7","journal-title":"Lancet"},{"key":"4743_CR2","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/S1470-2045(15)00139-4","volume":"16","author":"JW Valle","year":"2015","unstructured":"Valle JW, Wasan H, Lopes A et al (2015) Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial. Lancet Oncol 16:967\u2013978. https:\/\/doi.org\/10.1016\/S1470-2045(15)00139-4","journal-title":"Lancet Oncol"},{"key":"4743_CR3","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/s41572-021-00300-2","volume":"7","author":"PJ Brindley","year":"2021","unstructured":"Brindley PJ, Bachini M, Ilyas SI et al (2021) Cholangiocarcinoma. Nat Rev Dis Primers 7:65. https:\/\/doi.org\/10.1038\/s41572-021-00300-2","journal-title":"Nat Rev Dis Primers"},{"key":"4743_CR4","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.3390\/cancers13071569","volume":"13","author":"A Boileve","year":"2021","unstructured":"Boileve A, Hilmi M, Smolenschi C, Ducreux M, Hollebecque A, Malka D (2021) Immunotherapy in advanced biliary tract cancers. Cancers (Basel) 13:1569. https:\/\/doi.org\/10.3390\/cancers13071569","journal-title":"Cancers (Basel)"},{"issue":"8","key":"4743_CR5","doi-asserted-by":"publisher","first-page":"EVIDoa2200015","DOI":"10.1056\/EVIDoa2200015","volume":"1","author":"D-Y Oh","year":"2022","unstructured":"Oh D-Y et al (2022) Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid 1(8):EVIDoa2200015","journal-title":"NEJM Evid"},{"key":"4743_CR6","doi-asserted-by":"publisher","first-page":"S565","DOI":"10.1016\/j.annonc.2022.07.084","volume":"33","author":"DY Oh","year":"2022","unstructured":"Oh DY et al (2022) 56P Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+\u2009GC) in patients (pts) with advanced biliary tract cancer (BTC). Ann Oncol 33:S565\u2013S566","journal-title":"Ann Oncol"},{"issue":"1","key":"4743_CR7","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/cai2.60","volume":"2","author":"L Zhang","year":"2023","unstructured":"Zhang L et al (2023) Advances in medical treatment of advanced hepatobiliary and pancreatic cancer in 2022. Cancer Innov 2(1):36\u201351","journal-title":"Cancer Innov"},{"key":"4743_CR8","unstructured":"AstraZeneca (2022) Imfinzi (durvalumab) injection: Highlights of prescribing information. Retrieved from [https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761069s033lbl.pdf Last Accessed 05\/01\/2024"},{"issue":"6","key":"4743_CR9","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1002\/cpt.3063","volume":"114","author":"J He","year":"2023","unstructured":"He J, Zhijian D et al (2023) Population pharmacokinetics and exposure\u2013response analysis for the CTLA-4 inhibitor tremelimumab in metastatic NSCLC patients in the phase III POSEIDON study. Clin Pharmacol Ther 114(6):1375\u20131386","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"4743_CR10","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1023\/A:1020254823597","volume":"29","author":"U W\u00e4hlby","year":"2002","unstructured":"W\u00e4hlby U, Bouw MR, Jonsson EN, Karlsson MO (2002) Assessment of type I error rates for the statistical sub-model in NONMEM. J Pharmacokinet Pharmacodyn 29(3):251\u2013269","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"3","key":"4743_CR11","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1208\/s12248-009-9133-0","volume":"11","author":"RM Savic","year":"2009","unstructured":"Savic RM, Karlsson MO (2009) Importance of shrinkage in empirical Bayes estimates for diagnostics: problems and solutions. AAPS J 11(3):558\u2013569","journal-title":"AAPS J"},{"issue":"2","key":"4743_CR12","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1023\/A:1011555016423","volume":"28","author":"Y Yano","year":"2001","unstructured":"Yano Y, Beal SL, Sheiner LB (2001) Evaluating pharmacokinetic\/pharmacodynamic models using the posterior predictive check. J Pharmacokinet Pharmacodyn 28(2):171\u2013192","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"4","key":"4743_CR13","doi-asserted-by":"publisher","first-page":"E27","DOI":"10.1208\/ps040427","volume":"4","author":"U W\u00e4hlby","year":"2002","unstructured":"W\u00e4hlby U, Jonsson EN, Karlsson MO (2002) Comparison of stepwise covariate model building strategies in population pharmacokinetic-pharmacodynamic analysis. AAPS PharmSci 4(4):E27","journal-title":"AAPS PharmSci"},{"issue":"1","key":"4743_CR14","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/sj.clpt.6100241","volume":"82","author":"MO Karlsson","year":"2007","unstructured":"Karlsson MO, Savic RM (2007) Diagnosing model diagnostics. Clin Pharmacol Ther 82(1):17\u201320","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"4743_CR15","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","volume":"13","author":"M Bergstrand","year":"2011","unstructured":"Bergstrand M, Hooker AC, Wallin JE, Karlsson MO (2011) Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J 13(2):143\u2013151","journal-title":"AAPS J"},{"issue":"3","key":"4743_CR16","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1208\/s12248-011-9289-2","volume":"13","author":"A Khandelwal","year":"2011","unstructured":"Khandelwal A, Harling K, Jonsson EN, Hooker AC, Karlsson MO (2011) A fast method for testing covariates in population PK\/PD Models. AAPS J 13(3):464\u2013472","journal-title":"AAPS J"},{"issue":"2","key":"4743_CR17","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","volume":"34","author":"DR Cox","year":"1972","unstructured":"Cox DR (1972) Regression models and life-tables. J R Stat Soc Ser B Methodol 34(2):187\u2013202","journal-title":"J R Stat Soc Ser B Methodol"},{"issue":"6","key":"4743_CR18","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1111\/bcp.14662","volume":"87","author":"S Kawakatsu","year":"2021","unstructured":"Kawakatsu S, Bruno R, K\u00e5gedal M, Li C, Girish S, Joshi A et al (2021) Confounding factors in exposure-response analyses and mitigation strategies for monoclonal antibodies in oncology. Br J Clin Pharmacol 87(6):2493\u20132501","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"4743_CR19","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1002\/cpt.656","volume":"101","author":"C Liu","year":"2017","unstructured":"Liu C, Yu J, Li H, Liu J, Xu Y, Song P et al (2017) Association of time-varying clearance of nivolumab with disease dynamics and its implications on exposure response analysis. Clin Pharmacol Ther 101(5):657\u2013666","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"4743_CR20","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1002\/cpt.1953","volume":"108","author":"HI Dai","year":"2020","unstructured":"Dai HI, Vugmeyster Y, Mangal N (2020) Characterizing exposure-response relationship for therapeutic monoclonal antibodies in immuno-oncology and beyond: challenges, perspectives, and prospects. Clin Pharmacol Ther 108(6):1156\u20131170","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"4743_CR21","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1016\/j.ejca.2014.02.015","volume":"50","author":"MG McNamara","year":"2014","unstructured":"McNamara MG et al (2014) Neutrophil\/lymphocyte ratio as a prognostic factor in biliary tract cancer. Eur J Cancer 50(9):1581\u20131589","journal-title":"Eur J Cancer"},{"key":"4743_CR22","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-024-01060-1","author":"M Rimini","year":"2024","unstructured":"Rimini M et al (2024) Durvalumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin in biliary tract cancer: a real-world retrospective, multicenter study. Target Oncol 1\u201312. https:\/\/doi.org\/10.1007\/s11523-024-01060-1","journal-title":"Target Oncol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-024-04743-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-024-04743-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-024-04743-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T00:45:43Z","timestamp":1737074743000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-024-04743-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,17]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["4743"],"URL":"https:\/\/doi.org\/10.1007\/s00280-024-04743-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4576395\/v1","asserted-by":"object"}]},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,17]]},"assertion":[{"value":"13 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AA, KL, CF, JW, IX, MZ, SR, MG, and DZ are current employees of and shareholders in AstraZeneca.CC, CK and AP are former employees of AstraZeneca. DYO is a consultant and on the advisory board for: AstraZeneca, Novartis, Genentech\/Roche, Merck Serono, Bayer, Taiho, ASLAN, Halozyme, Zymeworks, BMS\/Celgene, BeiGene, Basilea, Turning Point, Yuhan, Arcus Biosciences, IQVIA, MSD, LG Chem, Astellas, Abbvie, J-Pharma, Mirati Therapeutics, Eutilex, Moderna, and Idience. DYO has also received research grants from AstraZeneca, Novartis, Array, Eli Lilly, Servier, BeiGene, MSD, and Handok.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the institutional review board\/ethics committee of each institution participating TOPAZ-1. Written informed consent was obtained from patients (or their legal guardian) to participate in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"23"}}